European Thyroid Association

39th Annual Meeting

Copenhagen, DENMARK | 3 – 6 September 2016

Scientific Programme

Monday, 5th September

Room 8+9+10+11

07.00 - 08.00 **ETA INDUSTRY-SPONSORED SATELLITE SYMPOSIUM 5**

08.00 - 09.30 **SYMPOSIA 3 & 4**

Room 8+9+10+11

SYMPOSIUM 3 (CLINICAL): **Recent advances in Graves' Orbitopathy**

Chairpersons: *George J. Kahaly, Germany and Anne Lene Riis, Denmark*

08.00-08.30 ETA Guidelines on Graves' Orbitopathy
Luigi Bartalena, Italy

08.30-09.00 Mortality and Morbidity in Graves' Orbitopathy
Thomas Brix, Denmark

09.00-09.30 Thyrotropin/IGF-1 receptor crosstalk in the pathogenesis of Graves' Orbitopathy
Susanne Neumann, USA

Room 13+15

SYMPOSIUM 4 (BASIC): **Triac treatment in AHD syndrome**

Chairpersons: *Caterina Di Cosmo, Italy and Juan Bernal, Spain*

08.00 - 08.30 Triac Treatment in the MCT8 KO Mouse
Heike Heuer, Germany

08.30 - 09.00 Triac Treatment in the MCT8 Zebrafish
Lior Appelbaum, Israel

09.00 - 09.30 Triac Treatment in AHD patients
Stephan Groeneweg, The Netherlands

09.30 – 10.00 **COFFEE BREAK**

10.00-12.00 ORAL SESSIONS 6 & 7

Room 8+9+10+11

ORAL SESSION 6: Clinical Aspects of Autoimmunity

Chairpersons: Thomas Brix, Denmark and Nils Knudsen, Denmark

10.00 – 10.15

EVALUATION OF RESPONSE DURING INTRAVENOUS GLUCOCORTICOID (IVGC) TREATMENT FOR MODERATE-TO-SEVERE AND ACTIVE GRAVES' ORBITOPATHY (GO): IS IT A GUIDANCE TO DECIDE WHETHER TREATMENT SHOULD BE CONTINUED OR WITHDRAWN?

Luigi Bartalena[1], Giovanni Veronesi[2], Gerassimos Krassas[3], Wilmar Wiersinga[4], Claudio Marcocci[5], Mario Salvi[6], Chantal Daumerie[7], Claire Bournaud[8], Matthias Stahl[9], Lorenza Sassi[2], Claudio Azzolini[2], Kostas Boboridis[10], Maarten Mourits[11], Maarten Soeters[11], baldeschi lelio[12], Marco Nardi[13], Nicola Currò[14], Antonella Boschi[12], Martine Bernard[15], Georg von Arx[16], Petros Perros[17], George Kahaly[18]

[1]*University of Insubria, Varese, Varese, Italy*
[2]*University of Insubria, Varese, Italy*
[3]*Panagia Hospital , Thessaloniki, Greece*
[4]*Academic Medical Center, Amsterdam, Netherlands*
[5]*Department of Clinical and Experimen, University of Pisa, Pisa, Italy*
[6]*Dipartimento Scienze Mediche, Endocrine Unit, Fondazione Irccs Cà Granda, Milano, Italy*
[7]*Cliniques Universitaires Saint-Luc, Endocrinologie, Brussels, Belgium*
[8]*Lyon University, Lyon, France*
[9]*Olten Spital, Olten, Switzerland*
[10]*Ahepa Hospital, Thessaloniki, Greece*
[11]*Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands*
[12]*Université Catholique de Louvain, Brussels, Belgium*
[13]*University of Pisa, Lucca, Italy*
[14]*Ophthalmology, Fondazione Irccs Cà Granda, Milan, Italy*
[15]*University of Lyon, Lyon, France*
[16]*Zentrum Fur Endokrine Orbitopathie, Olten, Switzerland*
[17]*Freeman Hospital, Newcastle-Upon-Tyne, United Kingdom*
[18]*Johannes Gutenberg University Medical Center, Mainz, Germany*

10.15 – 10.30

SIGHT-THREATENING GRAVES' ORBITOPATHY: EXPERIENCE OF THE MULTIDISCIPLINARY THYROID-EYE CONSULTATION OF THE UNIVERSITY HOSPITAL IN TOULOUSE, FRANCE

Tramunt Blandine[1], Philippe Imbert[2], GRUNENWALD Solange[3], Franck Boutault[4], Philippe Caron[5]

[1]*Service D'endocrinologie et Maladies Métaboliques, Chu Larrey, Toulouse, France*
[2]*Service D'ophtalmologie, Clinique du Parc, Toulouse, France*
[3]*Chu Larrey, Toulouse Cedex 9, France*
[4]*Service de Chirugie Maxillo-Faciale , Chu Pierre-Paul Riquet, Toulouse, France*
[5]*Chu Larrey, 7eme Etage/Chu Rangueil, Toulouse Cedex 9, France*

10.30 – 10.45

HIGHLY VARIABLE SENSITIVITY AND SPECIFICITY OF FOUR BINDING AND TWO BIO-ASSAYS FOR TSH-RECEPTOR ANTIBODIES

Tanja Diana[1], Christian Wüster[2], Michael Kanitz[1], George Kahaly[1]

[1]*Johannes Gutenberg University Medical Center, Mainz, Germany*
[2]*Endocrine Practice, Mainz, Germany*

10.45 – 11.00

HIGH CIRCULATING CXCL10 LEVELS IN NON-SEGMENTAL VITILIGO, IN PRESENCE OR ABSENCE OF AUTOIMMUNE THYROIDITIS.

Silvia Martina Ferrari[1], Poupak Fallahi[1], Giulia Santaguida[2], Camilla Virili[2], Ilaria Ruffilli[1], Francesca Ragusa[1], Marco Centanni[2], Alessandro Antonelli[1]

[1]*University of Pisa, Pisa, Italy*

[2]*Sapienza University of Rome, Dept of Medico-Surgical Sciences and Biotechnologies, Latina, Italy*

11.00 – 11.15

BREG IN HASHIMOTO THYROIDITIS ISOLATED OR ASSOCIATED TO FURTHER ORGAN-SPECIFIC AUTOIMMUNE DISEASES

Maria Giulia Santaguida[1], Camilla Virili[2], Ilenia Gatto[3], Giorgio Mangino[4], Ilaria Stramazzo[3], Marco Centanni[5]

[1]*"Sapienza" University of Roma, Dept of Medico-Surgical Sciences and Biotechnologies, Latina, Latina, Italy*

[2]*Dept of Experimental Medicine "sapienza" University of Rome, Latina, Italy, Dept Medico-Surgical Sciences and Biotechnologies, Rome, Italy*

[3]*"Sapienza" University of Roma, Latina, Italy*

[4]*"Sapienza" University of Roma, Dept of Medico-Surgical Sciences and Biotechnologies, Latina, Italy, Latina, Italy*

[5]*Sapienza University of Rome, Dept of Medico-Surgical Sciences and Biotechnologies, Latina, Italy*

11.15 – 11.30

HIGH EFFECTIVENESS OF THERAPEUTIC PLASMA EXCHANGE IN REFRACTORY HYPERTHYROIDISM: ABOUT 17 CASES

Clotilde Saie[1], Ghander Cecile[1], Saheb Sami[1], Jumentier Natacha[2], Kharcha Fatima[1], Lemesle Didier[2], salwa baki[3], Nassiba Beghdadi[1], Laurence Leenhardt[4], Buffet Camille[1], Tresallet Christophe[5]

[1]*Hôpital Pitié Salpêtrière, Paris, France*

[2]*Hôpital Pitié Salpêtrière , Paris, France*

[3]*Hôpital Pitié Salpêtrière, Marrakesh, Morocco*

[4]*La Pitie Salpetriere Hospital, Thyroid and Endocrine Tumors Unit, Paris, France*

[5]*Hôpital Pitié Salpêtrière, Paris , France*

11.30 – 11.45

QUANTIFICATION OF MOTILITY DYSFUNCTION IN GRAVES' ORBITOPATHY (GO) BY ASSESSING CHANGES IN EYE MUSCLE DUCTIONS.

Mario Salvi[1], Irene Campi[2], Guia Vannucchi[3], Danila Covelli[4], Simona Simonetta[5], Nicola Currò[6]

[1]*Dipartimento Scienze Mediche, Endocrine Unit, Fondazione Irccs Cà Granda, Milano, Italy*

[2]*Fondazione Irccs Ca' Granda, Endocrine Unit, Milan, Italy*

[3]*Endocrine Unit, Fondazione Policlinico Irccs, Milan, Italy, Milano, Italy*

[4]*1graves' Orbitopathy Unit, Endocrinology, Fondazione Ca' Granda Irccs, University of Milan, Italy , Medical Sciences, Milano, Italy*

[5]*Ophthalmology Unit, Fondazione Irccs Ca' Granda, Milan, Italy*

[6]*Ophthalmology, Fondazione Irccs Cà Granda, Milan, Italy*

11.45 – 12.00

GRAVES ORBITOPATHY AFFECTS VISUAL FUNCTION AND APPEARANCE IN DIFFERENT MANNERS

Danilo Villagelin [1], Roberto Bernado Dos Santos[2], João Hamilton Romaldini[2], Ana Paula Comarella[3], Natassia Bufalo[3], Karina Colombera Peres[3], Laura Ward[3]

[1]*Pont. Universidade Catolica Campinas, Campinas, Brazil*

[2]*Pontificia Universidade Catolica Campinas, Campinas, Brazil*

[3]*Laboratory of Cancer Molecular Genetics, University of Campinas, Campinas, Brazil*

Room 13 + 15

ORAL SESSION 7 (BASIC): MTC and Anaplastic Thyroid Cancer

Chairpersons: Laura Fugazzola, Italy and Kristian Winther, Denmark

10.00 – 10.15

GENETIC ANALYSIS OF ANAPLASTIC THYROID CANCER

Naveen Ravi[1], Eleanor Woodward[1], Andrea Biloglav[1], Lars Ekblad[2], Johan Wennerberg[2], Kajsa Paulsson[3]

[1]*Bmc C13, Lund University, Lund, Sweden*
[2]*Lund University, Lund, Sweden*
[3]*Bmc C13,Lund University, Lund, Sweden*

10.15 – 10.30

EVALUATION OF THE ANTINEOPLASTIC ACTIVITY OF VANDETANIB, AND LENVATINIB IN PRIMARY ANAPLASTIC THYROID CANCER CELLS, OBTAINED FROM FINE NEEDLE ASPIRATION.

Silvia Martina Ferrari[1], Poupak Fallahi[1], Concettina La Motta[2], Gabriele Materazzi[3], David Galleri[3], Alessandro Antonelli[1]

[1]*University of Pisa, Pisa, Italy*
[2]*Department of Pharmaceutical Science, University of Pisa , Pisa, Italy*
[3]*Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy*

10.30 – 10.45

SYNERGISTIC ANTI-CANCER ACTIVITY OF THE HDAC INHIBITOR, N-HYDROXY-7-(2-NAPHTHYLTHIO) HEPTANOMIDE (HNHA) AND SORAFENIB ON ANAPLASTIC THYROID CANCER IN VITRO AND IN VIVO

Seok-Mo Kim[1], Ki Cheong Park[1], Soo Young Kim[1], Hyeung Kyoo Kim[1], Bup-Woo Kim[1], Yong Sang Lee[1], Hang-Seok Chang[1], Cheong Soo Park[1]

[1]*Thyroid Cancer Center, Gangnam Severance Hospital, Seoul, Korea, Rep. of South*

10.45 – 11.00

TREATMENT OUTCOMES OF SORAFENIB AND LENVATINIB FOR ADVANCED THYROID CANCERS AND ANAPLASTIC THYROID CANCERS

Hiroyuki Iwasaki[1], Hiroyaka Nakayama[2], Nobuyasu Suganuma[1], Tatsuya Yoshida[1], Takashi Yamanaka[1], Shinsuke Hatori[3], Satoru Shimizu[1]

[1]*Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan*
[2]*Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan*
[3]*Department of Surgery, Hiratsuka Kyosai Hospital, Hiratsuka, Japan*

11.00 – 11.15

CALCITONIN RECEPTOR (CTR) EXPRESSION IN MEDULLARY THYROID CANCER (MTC) AND POSSIBLE CLINICAL IMPLICATIONS.

Virginia Cappagli[1], Catarina Soares Potes[2], Luciana Bueno Ferreira[3], Catarina Eloy[3], Cristina Romei[1], Rossella Elisei[1], Manuel Sobrinho-Simões[3], Peter J. Wookey[4], Paula Soares[3]

[1]*Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy*
[2]*Instituto de Investigação e Inovação Em Saúde, Universidade Do Porto, Porto, Portugal*
[3]*Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal*
[4]*Department of Medicine at Austin Health, University of Melbourne, Parkville, Australia*

11.15 – 11.30

THE MUTATION PROFILE OF MEDULLARY THYROID CARCINOMA CAN BE DIFFERENT IN PRIMARY AND METASTATIC TISSUES

Cristina Romei[1], Francesca Casella[1], Alessia Tacito[1], Raffaele Ciampi[1], Eleonora Molinaro[1], Laura Agate[1], Valeria Bottici[1], Antonio Matrone[1], Rossella Elisei[1]

[1]*Section of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Department of Endocrinology, Pisa, Italy*

11.30 – 11.45

EXPERIENCE FROM THE ADMINISTRATION OF TYROSINE KINASE INHIBITORS (TKI) IN PATIENTS WITH METASTATIC PROGRESSIVE MEDULLARY THYROID CARCINOMA (MTC) IN A REFERRAL CENTRE IN GREECE

Elli Anagnostou[1], Katerina Saltiki[2], Vasiliki Vasiliou[2], Constantinos Tsigkos[2], Lamprini Papanastasiou[2], Maria Alevizaki[2]

[1]*Endocrine Unit, Dept Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece, Athens, Greece*

[2]*Endocrine Unit, Dept Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece*

11.45 – 12.00

THE ASSOCIATION BETWEEN TERT PROMOTER MUTATIONS AND MORTALITY IN PATIENTS WITH THYROID CANCER

Tae Hyuk Kim[1], Youngnam Kim[1], Hyein Kim[1], Ho-Su Kim[1], Sun Wook Kim[1], Jae Hoon Chung[2]

[1]*Samsung Medical Center, Seoul, Korea, Rep. of South*

[2]*Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Seoul, Korea, Rep. of South*

12.00 - 13.00 **POSTER DISCUSSION P3 & LUNCH**

The poster session will start with a one minute slide presentation of the poster work, which will be moderated by the session chair. Subsequently the attendees of the poster session will discuss individually the poster with the presenter

Room 1	**Poster Session P3-01 Clinical Thyroidology** *Chairperson: Philippe Caron, France.*
Room 2	**Poster Session P3-02 Hypothyroidism 2, Children + Regulation** *Chairperson: Jose Moreno, Spain*
Room 3+4	**Poster Session P3-03 Goiter 2 and Environmental** *Chairperson: Leonidas Duntas, Greece*
Room 16	**Poster Session P3-04 Cardio, Brain and Metabolism** *Chairperson: Frans Brandt, Denmark.*
Room 14	**Poster Session P3-05 Thyroid Cancer Diagnostic III** *Chairperson: Georg Brabant, Germany*
Room 12	**Poster Session P3-06 Thyroid Cancer - Clinical II** *Chairperson: Tania Pilli, Italy*
Room 13+15	**Poster Session P3-07 Thyroid Cancer - Clinical III** *Chairperson: Torquil Watt, Denmark.*
East Lounge / 8+9+10+11	**Poster Session P3-08 Basic Autoimmunity and Thyroidology** *Chairperson: Marie-Christine Many, Belgium*

Room 8+9+10+11

13.00 - 14.00 **ETA INDUSTRY-SPONSORED SATELLITE SYMPOSIUM 6**

14.00-14.45 **MEET-THE-EXPERT 5 - 8**

Room 8+9+10+11	**MTE 5 -** New guidelines in thyroid nodules and cancer *Furio Pacini, Italy and Martin Schlumberger, France*
Room 13+15	**MTE 6 -** Biomarkers of TH action - Fact or Fiction? *Georg Brabant, Germany*
Room 12	**MTE 7 -** CRISPR/CAS making bespoke models *Frederic Flamant, France*
Room 14	**MTE 8 -** Abnormal thyroid function in children *Marek Niedziela, Poland*

14.45-15.00 **COFFEE BREAK**

15.00-17.00 ORAL SESSIONS 8 & 9

Room 8+9+10+11

ORAL SESSION 8 (CLINICAL): Thyroid Cancer Therapeutics

Chairpersons: *Johannes Smit, The Netherlands and Steen Bonnema, Denmark*

15.00 – 15.15

LONG-TERM HEALTH-RELATED QUALITY OF LIFE, FATIGUE, AND ANXIETY AND DEPRESSION IN ADULT SURVIVORS OF PEDIATRIC DIFFERENTIATED THYROID CARCINOMA

Marloes Nies[1], Mariëlle S. Klein Hesselink[1], Gea A. Huizinga[2], Esther Sulkers[2], Adrienne H. Brouwers[3], Johannes G. M. Burgerhof[4], Eveline W. C. M. van Dam[5], Bas Havekes[6], Marry M. van den Heuvel-Eibrink[7], Eleonora P. M. Corssmit[8], Leontien C. M. Kremer[9], Romana T. Netea-Maier[10], Heleen J. H. van der Pal[11], Robin P. Peeters[12], John T. M. Plukker[13], Cécile M. Ronckers[9], Hanneke M. van Santen[14], Wim J. E. Tissing[15], Thera P. Links[1], Gianni Bocca[16]

[1]*University of Groningen, University Medical Center Groningen , Department of Endocrinology, Groningen, Netherlands*
[2]*University of Groningen, University Medical Center Groningen , Wenckebach Institute, School of Nursing and Health, Groningen, Netherlands*
[3]*University of Groningen, University Medical Center Groningen , Department of Nuclear Medicine and Molecular Imaging, Groningen, Netherlands*
[4]*University of Groningen, University Medical Center Groningen , Department of Epidemiology, Groningen, Netherlands*
[5]*Vu University Medical Center, Department of Internal Medicine, Amsterdam, Netherlands*
[6]*Maastricht University Medical Center, Department of Internal Medicine, Division of Endocrinology, Maastricht, Netherlands*
[7]*Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Oncology, Rotterdam, Netherlands*
[8]*Leiden University Medical Center, Department of Internal Medicine, Division of Endocrinology, Leiden, Netherlands*
[9]*Academic Medical Center, Emma Children's Hospital, Department of Pediatric Oncology, Amsterdam, Netherlands*
[10]*Radboud University Medical Center, Division of Endocrinology, Nijmegen, Netherlands*
[11]*Academic Medical Center, Emma Children's Hospital, Department of Medical Oncology, Department of Pediatric Oncology, Amsterdam, Netherlands*
[12]*Erasmus Medical Center, Department of Internal Medicine, Rotterdam Thyroid Center, Rotterdam, Netherlands*
[13]*University of Groningen, University Medical Center Groningen , Department of Surgical Oncology, Groningen, Netherlands*
[14]*University Medical Center Utrecht, Wilhelmina Children's Hospital, Department of Pediatrics, Utrecht, Netherlands*
[15]*University of Groningen, Beatrix Children's Hospital, Department of Pediatric Oncology, Groningen, Netherlands*
[16]*University of Groningen, Beatrix Children's Hospital, Department of Pediatric Endocrinology, Groningen, Netherlands*

15.15 – 15.30

REAL-LIFE PRACTICES IN THE INITIAL TREATMENT OF DTCS IN ITALY: AN ANALYSIS OF PROSPECTIVE DATA COLLECTED BY THE ITALIAN THYROID CANCER OBSERVATORY

Livia Lamartina[1], Giorgio Grani[1], Alfredo Pontecorvi[2], Celestino Pio Lombardi[2], Rocco Bellantone[2], Emanuela Arvat[3], Efisio Puxeddu[4], Maria Chiara Zatelli[5], Massimo Torlontano[6], Teresa Montesano[7], Gianluca Aimaretti[8], Fabio Monzani[9], Fabio Orlandi[10], Cecilia Francese[11], Paolo Limone[12], Giovanna Spiazzi[13], Laura Fugazzola[14], Ezio Ghigo[15], Marco Attard[16], Alessandro Antonelli[17], Giuseppe Lucisano[18], Antonio Nicolucci[18], Cosimo Durante[1], Sebastiano Filetti[1]

[1]*Department of Internal Medicine and Medical Specialties, University of Rome Sapienza, Rome, Italy*
[2]*Division of Endocrinology, "Agostino Gemelli" School of Medicine, Catholic University of the Sacred Heart, Rome, Italy*
[3]*School of Medicine, University of Turin, Turin, Italy*
[4]*Department of Medicine, University of Perugia, Perugia, Italy*
[5]*Section of Endocrinology and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy*
[6]*Department of Medical Science, Ospedale Casa Sollievo Della Sofferenza-Irccs, San Giovanni Rotondo (Foggia), Italy*
[7]*Department of Nuclear Medicine, University of Rome Sapienza, Rome, Italy*
[8]*Endocrinology, Department of Translational Medicine, Università del Piemonte Orientale "A. Avogadro", Novara, Italy*
[9]*Geriatrics Unit, Department of Clinical & Experimental Medicine, University of Pisa, Pisa, Italy*
[10]*Division of Internal Medicine, Department of Medical Sciences, Gradenigo Hospital, University of Turin, Turin, Italy*
[11]*Endocrinology Division, Salerno, Italy*
[12]*Division of Endocrinology, Diabetology and Metabolism, Mauriziano Umberto I Hospital, , Turin, Italy*
[13]*Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy*
[14]*University of Milan, Milan, Italy*
[15]*Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, Molinette Hospital, , A.O.U. Città Della Salute e Della Scienza DI Torino, University of Turin, Turin, Italy*
[16]*Division of Endocrinology, Cervello Hospital, Palermo, Italy*

[17]*Department of Clinical and Experimental Medicine, University of Pisadepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy*
[18]*Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy*

15.30 – 15.45

DIASTOLIC DYSFUNCTION IS COMMON IN LONG-TERM SURVIVORS OF PEDIATRIC DIFFERENTIATED THYROID CARCINOMA

Marielle Klein Hesselink[1], Gianni Bocca[2], Yoran Hummel[3], Adrienne Brouwers[4], Johannes Burgerhof[5], Eveline van Dam[6], Jourik Gietema[7], Bas Havekes[8], Marry van den Heuvel-Eibrink[9], Eleonora Corssmit[10], Leontien Kremer[11], Romana Netea-Maier[12], Heleen van der Pal[13], Robin Peeters[14], John Plukker[15], Cecile Ronckers[16], Hanneke van Santen[17], Peter van der Meer[3], Thera Links[1], Wim Tissing[18]
[1]*Department of Endocrinology, University Medical Center Groningen, Groningen, Netherlands*
[2]*Department of Pediatric Endocrinology, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands*
[3]*Department of Cardiology, University Medical Center Groningen, Groningen, Netherlands*
[4]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands*
[5]*Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands*
[6]*Department of Internal Medicine, Vu University Medical Center, Amsterdam, Netherlands*
[7]*Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands*
[8]*Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, Maastricht, Netherlands*
[9]*Department of Pediatric Oncology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, Netherlands*
[10]*Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, Netherlands*
[11]*Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands*
[12]*Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, Netherlands*
[13]*Department of Pediatric Oncology, Emma Children's Hospital, Academic Medical Center, Department of Medical Oncology, Academic Medical Center, Amsterdam, Netherlands*
[14]*Department of Internal Medicine, Erasmus Medical Center, Rotterdam Thyroid Center, Erasmus Medical Center, Rotterdam, Netherlands*
[15]*Department of Surgical Oncology, University Medical Center Groningen, Groningen, Netherlands*
[16]*Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam, Netherlands*
[17]*Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands*
[18]*Department of Pediatric Oncology, Beatrix Children's Hospital, University Medical Center Groningen, Groningen, Netherlands*

15.45 – 16.00

PREDICTORS OF VANDETANIB RESPONSE IN THE LOCALLY ADVANCED OR METASTATIC MEDULLARY THYROID CANCER: A SINGLE CENTER EXPERIENCE

Laura Valerio[1], Valeria Bottici[2], Antonio Matrone[2], Alessia Tacito[2], Francesca Casella[2], Cristina Romei[2], Paolo Vitti[2], Rossella Elisei[2]
[1]*Endocrine Unit, University of Pisa, Pisa, Italy*
[2]*Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy*

16.00 – 16.15

LONG-TERM SURGICAL RESULTS OF PATIENTS WITH LOCALLY ADVANCED PAPILLARY THYROID CANCER ONLY TO HAVE RECURRENT INFERIOR LARYNGEAL NERVE INVASION

Yuna Ogimi[1], Takashi Uruno[1], Kenichi Matsuzu[1], Tetsuyo Maeda[1], Chie Masaki[1], Tadatoshi Osaku[1], Junko Akaishi[1], Kiyomi Y. Hames[1], Chisato Tomoda[1], Akifumi Suzuki[1], Keiko Ohkuwa[1], Hiroshi Shibuya[1], Wataru Kitagawa[1], Mitsuji Nagahama[1], Kiminori Sugino[1], Koichi Ito[1]
[1]*Ito Hospital, Tokyo, Japan*

16.15 – 16.30

INHIBITION OF ERK DIMERIZATION BLOCKS THYROID TUMOR PROGRESSION

Miguel Zaballos[1], Adrián Acuña-Ruiz[1], Garcilaso Riesco-Eizaguirre[2], Piero Crespo[3], Pilar Santisteban[1]
[1]*Instituto de Investigaciones Biomédicas "Alberto Sols", Madrid, Spain*
[2]*Hospital Universitario de Móstoles, Madrid, Spain*
[3]*Instituto de Biomedicina Y Biotecnología de Cantabria, Santander, Spain*

16.30 – 16.45

MULTIKINASE INHIBITOR SP EFFECTS ON ALTERED PROLIFERATIVE PATHWAYS IN THYROID CANCER STEM-LIKE CELLS

Elisa Stellaria Grassi[1], Valentina Cirello[2], Carla Colombo[3], Valeria Vezzoli[1], Leonardo Vicentini[4], Luca Persani[5], Laura Fugazzola[6]

[1]*Laboratory of Endocrine and Metabolic Research, Irccs Istituto Auxologico Italiano, Milan, Italy*
[2]*Endocrine Unit, Fondazione Irccs Ca' Granda, Milan, Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy*
[3]*Endocrine Unit, Fondazione Irccs Ca' Granda, Milan, Department of Clinical Sciences and Community Health, University of Milan, Italy*
[4]*Endocrine Surgery Unit, Fondazione Irccs Ca' Granda, Milan, Milan, Italy*
[5]*Dept. of Clinical Sciences & Community Health, University of Milan, Division of Endocrine and Metabolic Diseases and Laboratory of Endocrine and Metabolic Research, Irccs Istituto Auxologico Italiano, Milan, Italy*
[6]*Endocrine Unit, Fondazione Irccs Ca' Granda, Milan, Department of Pathophysiology and Transplantation, University of Milan, Milan, Milan, Italy*

16.45 – 17.00

GLUCOSE-COATED SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES PREPARED BY METAL VAPOUR SYNTHESIS ARE ELECTIVELY INTERNALIZED IN THYROID TUMORS LINES EXPRESSING GLUT1 TRANSPORTER

Daniele Barbaro[1], Lorenzo Di Bari[2], Valentina Gandin[3], Claudio Evangelisti[4], Giovanni Vitulli[5], Elenora Schiavi[5], Cristina Marzano[6], Anna M. Ferretti[7], Piero Salvadori[5]

[1]*Spedali Riuniti DI Livorno, Endocrinology, Livorno, Italy*
[2]*Department of Chemistry University of Pisa, Pisa, Italy*
[3]*Department of Phramaceutical Science University of Padova, Padova, Italy*
[4]*Istitute of Molecular Science and Technology National Rearch Council, Milano, Italy*
[5]*Erre Due Spa, Livorno, Italy*
[6]*Department of Pharmaceutical Pharmacological Science University of Padova, Padova, Italy*
[7]*Institute of Molecular Science and Technology National Research Council, Milano, Italy*

Room 13+15

ORAL SESSION 9 (BASIC): T3 Signalling in Brain and Periphery

Chairpersons: *Lutz Schomburg, Germany and Hans Perrild, Denmark*

15.00 – 15.15

IMPAIRED MATERNAL THYROID HORMONE RECEPTOR A1 SIGNALING PROGRAMS OFFSPRING METABOLISM

Rebecca Oelkrug[1], Milica Vujovic[2], Lisbeth Harder[3], Beate Herrmann[4], Sogol Gachkar[1], Jens Mittag[5]

[1]*Center of Brain, Behavior and Metabolism, University of Lübeck, Lübeck, Germany*
[2]*Department of Cell & Molecular Biology, Karolinska Institutet, Stockholm, Sweden*
[3]*Center of Brain, Behavior and Metabolism, University of Lübeck, Luebeck, Germany*
[4]*University of Lübeck, Center of Brain, Behavior and Metabolism, Lübeck, Germany*
[5]*Universität zu Lübeck, Center of Brain, Behavior and Metabolism, Lübeck, Germany*

15.15 – 15.30

MIXTURES OF XENOBIOTICS FOUND IN HUMAN AMNIOTIC FLUID MODIFY EMBRYONIC THYROID HORMONE SIGNALLING AND BRAIN DEVELOPMENT

Jean-Baptiste FINI[1], Bilal MUGHAL[1], Sébastien Le Mével[1], Michelle Leemans[1], Mélodie Lettmann[1], Petra spirhanzlova[1], Pierre Affaticati[2], jean-Stéphane Joly[2], Barbara Demeneix[3]

[1]*Umr Cnrs 7221, Muséum National D'histoire Naturelle, Paris, France*
[2]*Cnrs/Tefor, Gif Sur Yvette, France*
[3]*Umr Cnrs 7221, Département Régulations, Développement et Diversité Moléculaire, Muséum National D'histoire Naturelle, Evolutions des Régulations Endocriniennes, Paris, France*

15.30 – 15.45

EPITHELIAL BMP-SMAD1/5 SIGNALING AND ENDOTHELIAL CELLS ARE REQUIRED FOR THYROID FOLLICLE DEVELOPMENT

Villacorte Mylah[1], Delmarcelle Anne-Sophie[1], Lernoux Manon[1], Bouquet Mahé[1], Lemoine Pascale[1], Bolsee Jennifer[1], Umans Lieve[2], Chuva de sousa lopez Susana[3], Van Der Smissen Patrick[1], Sasaki Takako[4], Bommer Guido[1], Henriet Patrick[1], Refetoff Samuel[5], Lemaigre Frédéric[1], Zwijsen An[2], Courtoy Pierre[1], Christophe Pierreux[6]

[1]*De Duve Institute, Brussels, Belgium*
[2]*Vib-Kul, Leuven, Belgium*
[3]*Lumc, Leiden, Netherlands*
[4]*Oita University, Oita, Japan*
[5]*Chicago University, Chicago, United States*
[6]*De Duve Institute, Université Catholique de Louvain, Bruxelles, Belgium*

15.45 – 16.00

CENTRAL HYPOTHYROIDISM AND BIALLELIC DEFECT NEAR THE D/ERY MOTIF OF THE TRHR GENE

Marta Garcia[1], Jesús González de Buitrago[2], Leonardo Pardo[3], Patricia M. Hinkle[4], Jose Moreno[5]

[1]*Thyroid Molecular Laboratory, Institute for Medical and Molecular Genetics (Ingemm), La Paz University Hospital. Autonomous University of Madrid., Madrid, Spain*
[2]*Department of Pediatrics, San Pedro de Alcántara Hospital., Cáceres, Spain*
[3]*Computational Medicine Laboratory, Biostatistics Unit, Faculty of Medicine, Autonomous University of Barcelona., Barcelona, Spain*
[4]*Department of Pharmacology and Physiology, University of Rochester Medical Center., Rochester, United States*
[5]*Thyroid Molecular Laboratory, Institute for Medical and Molecular Genetics (Ingemm), La Paz University Hospital, Autonomous University of Madrid, Madrid, Spain*

16.00 – 16.15

CENTRAL ROLE FOR THYROID HORMONE SIGNALING IN PERIPHERAL METABOLIC PLASTICITY

Stephanie Decherf[1], Seugnet Isabelle[2], Terrien Jeremy[3], De Vries Emmely[4], Anita Boelen[5], Fekete Csaba[6], Balazs Gereben[7], Ducos Bertrand[8], Serge Luquet[9], Marie-Stéphanie Clerget-Froidevaux[10], Barbara Demeneix[11]

[1]*Muséum National D'histoire Naturelle, Umr Cnrs 7221, Paris, France*
[2]*Umr 7221 "evolution of Endocrine Regulations" , National Museum of Natural History , 75005 Paris, France, France*
[3]*Team Bioadapt Umr Cnrs/Mnhn 7179, 91800 Brunoy, France*
[4]*Department of Clinical Chemistry, Laboratory of Endocrinology, Academic Medical Center, University of Amsterdam, 1105az Amsterdam, Netherlands*
[5]*Academic Medical Centre, Amsterdam, Netherlands*
[6]*Institute of Experimental Medicine, Hungarian Academy of Sciences, 1083 Budapest, Hungary*
[7]*Institute of Experimental Medicine, Lab Molecular Cell Metabolism, Budapest, Hungary*
[8]*Genomic Paris Centre, Institut de Biologie de L'ecole Normale Supérieure (Ibens), 75230 Paris , France*
[9]*Umr 8251 Team Coffee - Université Paris Diderot - Paris 7 , U.F.R. Sciences du Vivant Bâtiment Buffon, 75205 Paris Cedex 13, France*
[10]*Mnhn/Cnrs Umr7221, Paris, France*
[11]*Umr Cnrs 7221, Département Régulations, Développement et Diversité Moléculaire, Muséum National D'histoire Naturelle, Evolutions des Régulations Endocriniennes, Paris, France*

16.15 – 16.30

THYROID HORMONE T3 MAY PROTECT FROM FASTING INDUCED SKELETAL MUSCLE ATROPHY

Cecilia Verga Falzacappa[1], Claudia Mangialardo[2], Camilla Virili[3], Maria Giulia Santaguida[4], Viviana Moresi[5], Marco Centanni[6]

[1]*Medical Surgical Sciences and Biotechnologies Department,Sapienza, University of Rome, Pasteur Institute, Italy, Rome, Italy*

[2]*Pasteur Institute, Italy, Medical Surgical Sciences and Biotechnologies, Sapienza, Rome, Italy*

[3]*Dept of Experimental Medicine "sapienza" University of Rome, Latina, Italy, Dept Medico-Surgical Sciences and Biotechnologies, Rome, Italy*

[4]*Medico-Surgical Sciences and Biotechnologies Department, Medico-Surgical Sciences and Biotechnologies, Latina , Italy*

[5]*Saimlal Department, Sapienza, Rome, Italy*

[6]*Sapienza University of Rome, Dept of Medico-Surgical Sciences and Biotechnologies, Latina, Italy*

16.30 – 16.45

THE GENOMIC RESPONSE OF THE MOUSE THYROID TO IODINE OVERLOAD, AND THE ROLE OF THE NRF2 ANTIOXIDANT SYSTEM.

Panos Ziros[1], Dionysios Chartoumpekis[2], Ioannis Habeos[3], Adam Smith[4], Ana Claudia Marques[4], Gerasimos Sykiotis[1]

[1]*Lausanne University Hospital, Lausanne, Switzerland*

[2]*University of Pittsburgh Medical Center, Pittsburgh, United States*

[3]*University of Patras Medical School, Patras, Greece*

[4]*University of Lausanne, Lausanne, Switzerland*

16.45 – 17.00

3-IODOTHYRONAMINE AND TRACE AMINE-ASSOCIATED RECEPTOR 1 ARE INVOLVED IN THE EXPRESSION OF LONG-TERM POTENTIATION IN MOUSE ENTORHINAL CORTEX.

Alice Accorroni[1], Chiara Criscuolo[2], Martina Sabatini[3], Riccardo Donzelli[4], Alessandro Saba[5], Nicola Origlia[2], Riccardo Zucchi[5]

[1]*Scuola Superiore Sant'anna, Pisa, Italy*

[2]*Cnr Neuroscience Institute, Pisa, Italy*

[3]*Dept. of Pathology, University of Pisa, Dept. of Pathology, Pisa , Italy*

[4]*University of Pisa, Department of Pathology, Pisa, Italy*

[5]*University of Pisa, Pisa, Italy*

Room 8+9+10+11

17.10 - 17.50	**ETA PINCHERA PRIZE LECTURE**
Chairpersons:	*Furio Pacini, Italy and Colin Dayan, United Kingdom*

Room 8+9+10+11

18.00 – 19.15	**GENERAL ASSEMBLY**

20.00	**ETA - NETWORK DINNER**
	Teaterkælderen. Det Ny Teater, Gammel Kongevej, 1610 København V